Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 1 1

Status

Completed 20Recruiting 8Unknown 6Withdrawn 4Active not recruiting 4Terminated 3Suspended 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1CNS 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Persistent Infection 1Glioblastoma 1Condylomata Acuminata 1Colonic Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Vaccines × Clear all
NCT04015700 2026-05-07

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Washington University School of Medicine

Phase 1 Active not recruiting
9 enrolled 14 charts
CNS

Glioblastoma

NCT06011772 2026-03-11

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Active not recruiting
2 enrolled
Gastrointestinal

Colonic Neoplasms

NCT06243666 2025-07-31

Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Xiamen University

Active not recruiting
2,188 enrolled
Gynecologic

Persistent Infection, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms

NCT06866574 2025-07-31

A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males

Xiamen University

Phase 3 Active not recruiting
9,300 enrolled
Gastrointestinal

Anus Neoplasms, Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡